Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities.
Acazicolcept (267-400 μg/mouse; i.p.; twice a week; for 6 weeks) decreases dermal and pulmonary fibrosis and alleviates pulmonary hypertension[1].
References:
[1]. Cindy Orvain, et al. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. Arthritis Res Ther. 2022 Jan 5;24(1):13.